Nanomedicine--the power of proteins: a conversation with Lance Liotta and Emanual Petricoin. Interview by Barbara J Culliton.
Molecularly targeted cancer drugs have begun to usher in the promise of personalized medicine, where genetic tests determine whether a therapy is prescribed. Because these new drugs are costly, many insurers require gene tests as a precondition of payment. But there is still an element of doubt, because the drugs act on proteins, not genes. More accurate ways to match patients and therapies may come from proteomics, where scientists are developing methods for identifying the proteins that are active in diseased tissues. In this interview, Barbara Culliton discusses the promise of proteomics with Lance Liotta and Emanual Petricoin, two scientists operating at the frontiers of that field.
Liotta
Lance
L
Petricoin
Emanual
E
D015415:Biomarkers / Q000032:analysis; D030342:Genetic Diseases, Inborn / Q000473:pathology; D006801:Humans; D050997:Nanomedicine; D009369:Neoplasms / Q000235:genetics / Q000473:pathology; D040081:Protein Array Analysis; D011506:Proteins / Q000032:analysis*; D040901:Proteomics
D015415:Biomarkers; D011506:Proteins